Hepatic Encephalopathy Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hepatic encephalopathy market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.

The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.

The increasing prevalence of liver diseases is expected to drive the growth of the hepatic encephalopathy market in the coming years. Liver disease refers to any condition that affects the liver and impairs its functionality. Treatments for liver diseases, such as those for hepatic encephalopathy, can help alleviate symptoms, slow the progression of the disease, improve liver function, and reduce the occurrence of hepatic encephalopathy by better managing underlying conditions. This can potentially decrease both the frequency and severity of episodes, improving patients' overall quality of life. For example, in April 2024, the Office for Health Improvement and Disparities, a government department in the UK, reported that hospital admissions for liver disease continued to rise, reaching 155.2 per 100,000 population in the financial year ending 2023, up from 150.6 the previous year. As such, the increasing prevalence of liver diseases is fueling the growth of the hepatic encephalopathy market.

Rising healthcare expenditures are expected to drive the growth of the hepatic encephalopathy market. Healthcare expenditures refer to the total spending on healthcare services, products, and activities over a specific period, which can be measured at the individual, community, national, or global level. Increased healthcare spending can positively affect the availability and development of hepatic encephalopathy treatments by supporting advancements in diagnosis, treatment options, awareness, and patient care. For example, in December 2023, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% increase seen in 2021. As a result, the rise in healthcare expenditures will contribute to the growth of the hepatic encephalopathy market.

Prominent companies operating in the hepatic encephalopathy market are actively involved in the development of innovative drugs aimed at treating hepatic encephalopathy. These efforts are driven by the desire to gain a competitive edge and reinforce their market position. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, introduced the novel GR3027 (golexanolone) for the treatment of hepatic encephalopathy. GR3027 is an orally administered small molecule classified as a GABAA-receptor-modulating steroid antagonist (GAMSA), designed to counteract positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is undergoing clinical trials for the treatment of hepatic encephalopathy, specifically for chronic hepatic encephalopathy (CHE) in Phases I/IIa.

In September 2022, Genfit SA., a France-based biotechnology company, completed the acquisition of Versantis AG for an undisclosed sum. Through this strategic move, Genfit aims to expand its product pipeline to address other liver diseases characterized by unmet medical needs. Versantis, headquartered in Switzerland, is a biotechnology company specializing in the development of drugs for hepatic encephalopathy.

Major companies operating in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.

North America was the largest region in the hepatic encephalopathy market in 2024. The regions covered in hepatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms.

The main drug types of hepatic encephalopathy are antibiotics, laxatives, l-ornithine, l-aspartate and others. Antibiotics are a class of medications that are used to treat bacterial infections and helps lower the overall ammonia load in the body, which can contribute to the neurological symptoms associated with hepatic encephalopathy. The various route of administration including oral, intravenous and rectal which are distributed through various distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies.

The hepatic encephalopathy market research report is one of a series of new reports that provides hepatic encephalopathy market statistics, including hepatic encephalopathy industry global market size, regional shares, competitors with a hepatic encephalopathy market share, detailed hepatic encephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the hepatic encephalopathy industry. This hepatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.